Feasibility and challenges for sequential treatments in ALK-rearranged non-small-cell lung cancer
Background: Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) is a model disease for use of targeted therapies (TKI), which are administered sequentially to maximize patient survival. Methods: We retrospectively analyzed the flow of 145 consecutive TKI-treated ALK+ NSCLC...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 April 2021
|
| In: |
Frontiers in oncology
Year: 2021, Jahrgang: 11, Pages: 1-8 |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2021.670483 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fonc.2021.670483 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fonc.2021.670483/full 
|
| Verfasserangaben: | Mei Elsayed, Farastuk Bozorgmehr, Daniel Kazdal, Anna-Lena Volckmar, Holger Sültmann, Jürgen R. Fischer, Mark Kriegsmann, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1756579016 | ||
| 003 | DE-627 | ||
| 005 | 20230426092541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210429s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2021.670483 |2 doi | |
| 035 | |a (DE-627)1756579016 | ||
| 035 | |a (DE-599)KXP1756579016 | ||
| 035 | |a (OCoLC)1264417485 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a El Sayed, Mei |e VerfasserIn |0 (DE-588)1185583343 |0 (DE-627)1664958355 |4 aut | |
| 245 | 1 | 0 | |a Feasibility and challenges for sequential treatments in ALK-rearranged non-small-cell lung cancer |c Mei Elsayed, Farastuk Bozorgmehr, Daniel Kazdal, Anna-Lena Volckmar, Holger Sültmann, Jürgen R. Fischer, Mark Kriegsmann, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos |
| 264 | 1 | |c 20 April 2021 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.04.2021 | ||
| 520 | |a Background: Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) is a model disease for use of targeted therapies (TKI), which are administered sequentially to maximize patient survival. Methods: We retrospectively analyzed the flow of 145 consecutive TKI-treated ALK+ NSCLC patients across therapy lines. Suitable patients that could not receive an available next-line therapy ("attrition") were determined separately for various treatments, based on the approval status of the respective targeted drugs when each treatment failure occurred in each patient. Results: At the time of analysis, 70/144 (49%) evaluable patients were still alive. Attrition rates related to targeted treatments were approximately 25-30% and similar for administration of a second-generation (2G) ALK inhibitor (22%, 17/79) or any subsequent systemic therapy (27%, 27/96) after crizotinib, and for the administration of lorlatinib (27%, 6/22) or any subsequent systemic therapy (25%, 15/61) after any 2G TKI. The rate of chemotherapy implementation was 67% (62/93). Both administration of additional TKI (median overall survival [mOS] 59 vs. 41 months for multiple vs. one TKI lines, logrank p=0.002), and chemotherapy (mOS 41 vs. 16 months, logrank p<0.001) were significantly associated with longer survival. Main reason for patients foregoing any subsequent systemic treatment was rapid clinical deterioration (n=40/43 or 93%) caused by tumor progression. In 2/3 of cases (29/43), death occurred under the first failing therapy, while in 11/43 the treatment was switched, but the patient did not respond, deteriorated further, and died within 8 weeks. Conclusions: Despite absence of regulatory obstacles and no requirement for specific acquired mutations, 25-30% of ALK+ NSCLC patients forego subsequent systemic therapy due to rapid clinical deterioration, in several cases (approximately 1/3) associated with an ineffective first next-line choice. These results underline the need for closer patient monitoring and broader profiling in order to support earlier and better directed use of available therapies. | ||
| 650 | 4 | |a ALK-rearranged non-small-cell lung cancer | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a Sequential therapies | |
| 650 | 4 | |a tyrosine kinase inhibitors | |
| 700 | 1 | |a Bozorgmehr, Farastuk |d 1979- |e VerfasserIn |0 (DE-588)141921811 |0 (DE-627)632526734 |0 (DE-576)326848150 |4 aut | |
| 700 | 1 | |a Kazdal, Daniel |d 1983- |e VerfasserIn |0 (DE-588)114929650X |0 (DE-627)1009614088 |0 (DE-576)496635867 |4 aut | |
| 700 | 1 | |a Volckmar, Anna-Lena |d 1984- |e VerfasserIn |0 (DE-588)173874916 |0 (DE-627)698776666 |0 (DE-576)134713478 |4 aut | |
| 700 | 1 | |a Sültmann, Holger |d 1962- |e VerfasserIn |0 (DE-588)172777291 |0 (DE-627)697708144 |0 (DE-576)133633926 |4 aut | |
| 700 | 1 | |a Fischer, Jürgen |d 1953- |e VerfasserIn |0 (DE-588)133724484 |0 (DE-627)691747725 |0 (DE-576)300052510 |4 aut | |
| 700 | 1 | |a Kriegsmann, Mark |d 1987- |e VerfasserIn |0 (DE-588)103740324X |0 (DE-627)755668782 |0 (DE-576)39141870X |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 700 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d Lausanne : Frontiers Media, 2011 |g 11(2021) vom: Apr., Artikel-ID 670483, Seite 1-8 |h Online-Ressource |w (DE-627)684965518 |w (DE-600)2649216-7 |w (DE-576)35841184X |x 2234-943X |7 nnas |a Feasibility and challenges for sequential treatments in ALK-rearranged non-small-cell lung cancer |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g month:04 |g elocationid:670483 |g pages:1-8 |g extent:8 |a Feasibility and challenges for sequential treatments in ALK-rearranged non-small-cell lung cancer |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fonc.2021.670483 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fonc.2021.670483/full |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210429 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PC138659702 |e 950000PC138659702 |e 950900PC138659702 |e 50000PC138659702 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 10 |y j | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |e 50000PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 9 | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |e 910000PS139606106 |e 912000PS139606106 |k 0/910000/ |k 1/910000/912000/ |p 8 | ||
| 998 | |g 103740324X |a Kriegsmann, Mark |m 103740324X:Kriegsmann, Mark |d 910000 |d 912000 |d 50000 |e 910000PK103740324X |e 912000PK103740324X |e 50000PK103740324X |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 7 | ||
| 998 | |g 133724484 |a Fischer, Jürgen |m 133724484:Fischer, Jürgen |d 50000 |e 50000PF133724484 |k 0/50000/ |p 6 | ||
| 998 | |g 172777291 |a Sültmann, Holger |m 172777291:Sültmann, Holger |d 50000 |e 50000PS172777291 |k 0/50000/ |p 5 | ||
| 998 | |g 173874916 |a Volckmar, Anna-Lena |m 173874916:Volckmar, Anna-Lena |d 910000 |d 912000 |e 910000PV173874916 |e 912000PV173874916 |k 0/910000/ |k 1/910000/912000/ |p 4 | ||
| 998 | |g 114929650X |a Kazdal, Daniel |m 114929650X:Kazdal, Daniel |d 910000 |d 912000 |e 910000PK114929650X |e 912000PK114929650X |k 0/910000/ |k 1/910000/912000/ |p 3 | ||
| 998 | |g 141921811 |a Bozorgmehr, Farastuk |m 141921811:Bozorgmehr, Farastuk |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PB141921811 |e 950000PB141921811 |e 950900PB141921811 |e 50000PB141921811 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 2 | ||
| 998 | |g 1185583343 |a El Sayed, Mei |m 1185583343:El Sayed, Mei |d 910000 |d 950000 |d 950900 |e 910000PE1185583343 |e 950000PE1185583343 |e 950900PE1185583343 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1756579016 |e 3919796659 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Mei Elsayed, Farastuk Bozorgmehr, Daniel Kazdal, Anna-Lena Volckmar, Holger Sültmann, Jürgen R. Fischer, Mark Kriegsmann, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Feasibility and challenges for sequential treatments in ALK-rearranged non-small-cell lung cancer","title_sort":"Feasibility and challenges for sequential treatments in ALK-rearranged non-small-cell lung cancer"}],"person":[{"family":"El Sayed","role":"aut","given":"Mei","display":"El Sayed, Mei"},{"role":"aut","given":"Farastuk","display":"Bozorgmehr, Farastuk","family":"Bozorgmehr"},{"display":"Kazdal, Daniel","given":"Daniel","role":"aut","family":"Kazdal"},{"display":"Volckmar, Anna-Lena","given":"Anna-Lena","role":"aut","family":"Volckmar"},{"family":"Sültmann","role":"aut","given":"Holger","display":"Sültmann, Holger"},{"family":"Fischer","role":"aut","given":"Jürgen","display":"Fischer, Jürgen"},{"role":"aut","display":"Kriegsmann, Mark","given":"Mark","family":"Kriegsmann"},{"family":"Stenzinger","role":"aut","display":"Stenzinger, Albrecht","given":"Albrecht"},{"family":"Thomas","role":"aut","given":"Michael","display":"Thomas, Michael"},{"family":"Christopoulos","role":"aut","display":"Christopoulos, Petros","given":"Petros"}],"physDesc":[{"extent":"8 S."}],"id":{"doi":["10.3389/fonc.2021.670483"],"eki":["1756579016"]},"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"20 April 2021"}],"note":["Gesehen am 29.04.2021"],"recId":"1756579016","relHost":[{"disp":"Feasibility and challenges for sequential treatments in ALK-rearranged non-small-cell lung cancerFrontiers in oncology","physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"11(2021) vom: Apr., Artikel-ID 670483, Seite 1-8","pages":"1-8","year":"2021","extent":"8","volume":"11"},"title":[{"title":"Frontiers in oncology","title_sort":"Frontiers in oncology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"issn":["2234-943X"],"eki":["684965518"],"zdb":["2649216-7"]},"language":["eng"],"recId":"684965518","pubHistory":["2011 -"],"origin":[{"publisherPlace":"Lausanne","publisher":"Frontiers Media","dateIssuedDisp":"2011-","dateIssuedKey":"2011"}],"note":["Gesehen am 07.11.13"]}]} | ||
| SRT | |a ELSAYEDMEIFEASIBILIT2020 | ||